Developer docs
API playgroundTry for free, no card

Search company profiles

Nushama

Full company profile

uuid000gtjj

Namestring
Nushama
Legal namestring
Nushama
Websiteurl
nushama.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nushama is a privately held, for-profit operator of medically supervised psychedelic wellness clinics founded in 2021 and headquartered at 515 Madison Avenue, New York, with 11–50 employees (per LinkedIn). It runs a three-location network — Midtown Manhattan, Rockland County NY, and Aventura FL — delivering IV ketamine infusions, FDA-approved Spravato (esketamine), accelerated One-Day TMS, NAD+ IV therapy, and Niagen (NR) therapy to patients with treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, postpartum depression, migraines, suicidal ideation, palliative care needs, and alcohol use disorder. Treatment protocols follow a structured arc — psychiatric and medical intake, preparation sessions, six IV ketamine sessions over three to six weeks (or Spravato induction twice weekly for four weeks with weekly maintenance), continuous vital-sign monitoring, and integration coaching — augmented by a published 2025 real-world PTSD outcomes study (75.21% clinically meaningful improvement, 61.54% full remission) and a KARE partnership with Awakn Life Sciences for alcohol use disorder.

The revenue model is hybrid professional-services and subscription/recurring: IV ketamine and TMS are predominantly out-of-pocket session fees (typically six-session protocols); Spravato is in-network with Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare; NAD+ and Niagen are per-session or bundled add-ons; financing is available via CareCredit and HSA/FSA. Pricing accessibility is extended through the Hero's Journey scholarship program (a 25% discount for first responders and veterans) and monthly financial-based scholarships. Go-to-market combines direct-to-consumer intake, healthcare provider referrals via a dedicated for-providers portal, and community-led growth (bi-weekly integration circles, PR coverage in the NYT, WSJ, Elle, Good Morning America, New York Magazine, and Forbes). Operations are supported by HIPAA-compliant privacy protocols, FDA REMS certification for Spravato, and DEA-licensed dosing oversight led by Chief Medical Officer Dr. Steven Radowitz, alongside co-founders Jay Godfrey and Richard Meloff.

Short descriptiontext

Nushama operates a three-clinic psychedelic wellness network delivering medically supervised IV ketamine, FDA-approved Spravato, accelerated TMS, and NAD+ therapy for treatment-resistant depression, PTSD, anxiety, and trauma in the New York metro area and South Florida.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ketamine infusion therapy, psychedelic wellness services, treatment-resistant depression, spravato esketamine treatment, accelerated TMS therapy
Industry2 codes
PRIMARYEDALAFAB
Mental Health Counseling & Psychotherapy Services
Education/Student Services & Campus Operations/Student Health, Counseling & Wellness Services
SECONDARYBPAGAEAO
Substance Use Recovery & Harm Reduction Support Services
Business & Public Services/Nonprofit, NGO & Social Services/Social Services & Community Support (Food, Housing, Family)
NAICS code1 code
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code2 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Ketamine Therapy Clinics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1IV Ketamine Infusions
TypeProfessional Services
Description

Intravenous ketamine therapy administered in a clinic setting. Typically an out-of-pocket expense, though superbills can be provided for potential out-of-network insurance reimbursement. Six-session protocols generate recurring service revenue per patient.

nushama.com
2Spravato (Esketamine) Treatment
TypeSubscription Recurring
Description

FDA-approved esketamine nasal spray for treatment-resistant depression and MDD with acute suicidal ideation. Covered by in-network insurance plans including Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance.

nushama.com
3One-Day TMS
TypeProfessional Services
Description

Accelerated transcranial magnetic stimulation (TMS) services compressing typical six-week treatment into accelerated protocols for time-constrained patients. Revenue generated per session.

nushama.com
4NAD+ and Niagen Therapy
TypeProfessional Services
Description

Cellular support therapies offered as complementary treatments to ketamine, potentially billed per session or as part of bundled treatment protocols.

nushama.com
5CareCredit Financing
TypeAffiliate Referral
Description

Third-party patient financing through CareCredit for out-of-pocket treatments, enabling payment plans for patients who cannot afford full upfront costs.

nushama.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain, Technology or R&D, Others
Pricing details3 tiers
1Hero's Journey Program — 25% discount for first responders and veterans
ModelSubscriptionBilling cadenceMonthly
Notes

Active-duty military, veterans, police officers, fire department members, EMT workers, nurses, and teachers receive 25% discount on all services. Contact via phone (646-394-9996) or email (info@nushama.com).

nushama.com
2Integration Circles — ongoing support included
ModelSubscriptionBilling cadenceMonthly
Notes

Bi-weekly integration circles available year-round at no additional cost for current and past members. Part of the standard treatment protocol.

nushama.com
3Cancellation Policy — Journey appointments
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Journey appointment cancellation without proper notice (by noon the previous business day) incurs a $350 fee. Intake appointments cancelled without proper notice incur a $50 fee. Therapy appointments: $50 (existing) or $100 (new) for late cancellation.

nushama.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 record
1Hero's Journey Program
Description

Scholarship program offering 25% discount for first responders and veterans on all ketamine therapy services

nushama.com
Core offering1 text field

Nushama operates a network of medically supervised psychedelic wellness clinics that administer intravenous (IV) ketamine infusions and Spravato (esketamine) nasal spray as primary treatments, supported by accelerated one-day transcranial magnetic stimulation (TMS), NAD+ IV therapy, and NIAGEN (NR) supplementation. Treatments target treatment-resistant depression, PTSD, anxiety, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, palliative care, and alcohol use disorder (via the KARE protocol under partnership with Awakn Life Sciences). Services are delivered across three physical clinic locations in Manhattan, Rockland County (NY), and Aventura (FL), with psychiatric intake, continuous medical monitoring, preparation sessions, six-session IV ketamine protocols over three to six weeks, and bi-weekly integration circles forming the standard treatment arc.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 70-90% response rate for ketamine infusion vs. 30-60% for standard antidepressants
+4 more records
Product overview1 text field

Nushama is a network of medically-supervised psychedelic wellness clinics offering ketamine-assisted therapy for mental health conditions. The core offering consists of IV Ketamine Infusions and Spravato (FDA-approved esketamine nasal spray) for conditions including treatment-resistant depression, anxiety, PTSD, and trauma. Adjacent services include One-Day TMS (accelerated transcranial magnetic stimulation), NAD+ Therapy, and NIAGEN (NR) Therapy for cellular support. Treatment protocols include preparation sessions, six IV ketamine sessions over three to six weeks, medical monitoring, and integration support. Financial access programs include the Hero's Journey 25% discount for first responders and veterans, and monthly financial-based scholarships. The company operates three locations in New York City, Rockland County, and Aventura, Florida.

Product and service6 records
1Ketamine Infusions
CategoryPsychedelic-assisted therapy / ketamine infusion
Description

Intravenous ketamine infusions administered in a medically supervised clinical setting for treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, and other mood disorders; delivered as a six-session protocol over three to six weeks with preparation, continuous vital monitoring, and integration support. Typically paid out-of-pocket with superbills available for potential out-of-network insurance reimbursement.

2Spravato (Esketamine) Treatment
CategoryFDA-approved psychedelic-assisted therapy
Description

FDA-approved esketamine nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation, administered under FDA REMS supervision with two-hour post-administration observation. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance, and is covered in-network by Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare.

3One-Day TMS (Accelerated Transcranial Magnetic Stimulation)
CategoryNeuromodulation / TMS therapy
Description

Accelerated transcranial magnetic stimulation protocol that compresses the typical multi-week TMS course into a single-day treatment for time-constrained patients such as executives and busy professionals, delivered as a complement or alternative to ketamine for rapid depression relief.

4NAD+ IV Therapy
CategoryCellular / longevity IV therapy
Description

Intravenous nicotinamide adenine dinucleotide (NAD+) infusions used to support cellular energy, neural recovery, and physical rehabilitation, offered as a complement to ketamine treatment or as a standalone cellular-recovery and longevity service.

5NIAGEN (NR) Therapy
CategoryCellular / longevity supplementation therapy
Description

Nicotinamide Riboside (Niagen/NR) supplementation therapy delivered to support cellular repair, mitochondrial function, and to complement the neuroplastic effects of ketamine treatment.

6Hero's Journey Program
CategoryFinancial assistance / access program
Description

Financial-assistance access program providing a 25% discount on all Nushama services for active-duty military, veterans, police officers, fire department members, EMT workers, nurses, and teachers, supporting evidence-led psychedelic therapy access for these populations.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nushama partnered with Awakn Life Sciences to offer the KARE (Ketamine-Assisted Rehabilitation and Enhancement) protocol for treating alcohol use disorder. The protocol demonstrated 86% efficacy for abstinence after six months in clinical trials — an unprecedented clinical study result. This partnership extends Nushama's evidence-based treatment portfolio with a rigorously studied psychedelic therapy protocol for addiction.

Strategic tierMinorTypeOthers
Description

Nushama uses Rater8 for member reviews and testimonials, displaying review links and ratings from verified patients on team member profile pages (Dr. Steven Radowitz, Dr. Robert Glatter, Dr. Mark Braunstein). Review links are prominently displayed on the website to build credibility and social proof.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Spravato (Janssen / Johnson & Johnson)
TypeBroad incumbent
Description

Janssen's Spravato (esketamine) is the FDA-approved nasal spray version of ketamine that Nushama also administers under REMS. As the pharmaceutical incumbent, Spravato defines the regulatory and reimbursement landscape within which Nushama operates its IV ketamine and esketamine services.

TypeBroad incumbent
Description

Compass Pathways is a clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Broader psychedelic therapy incumbent that competes for the same patient population and share-of-mind in psychedelic-assisted mental health treatment.

TypeRegional player
Description

Restore Hyper Wellness operates a national franchise of wellness centers offering IV therapy, NAD+, cryotherapy, and other recovery modalities. Comparable in NAD+ and longevity-adjacent service offerings and franchise-style clinic delivery, though Restore focuses on wellness more than psychiatric care.

4Field Trip Health
TypeDirect peer
Description

Field Trip Health was a publicly listed psychedelic therapy clinic network offering ketamine-assisted psychotherapy in premium locations across North America. Closest historical direct peer to Nushama in clinic model, target patient, and therapy modality.

TypeDirect peer
Description

Mindbloom is a leading at-home ketamine therapy provider offering guided psychedelic treatment via telehealth and remote clinician supervision. Direct competitor for ketamine-treated mood disorders, competing for the same patient demographic with a different delivery model.

TypeDirect peer
Description

Better U operates ketamine therapy clinics offering supervised IV ketamine treatments for mood disorders, anxiety, and PTSD in a clinical setting. Direct peer in outpatient ketamine clinic model targeting treatment-resistant populations.

TypeDirect peer
Description

KCLA is one of the oldest and largest ketamine-only specialty outpatient clinics in the U.S., offering IV ketamine protocols for depression, PTSD, and chronic pain. Direct peer in clinic-based ketamine therapy for treatment-resistant mental health conditions.

TypeOthers
Description

Awakn Life Sciences is a clinical-stage psychedelics company whose KARE protocol for alcohol use disorder Nushama licenses and delivers clinically. Direct partnership counterparty and adjacent specialty psychedelic therapeutics developer.

TypeDirect peer
Description

Actify operates a national network of clinics offering ketamine infusion therapy combined with TMS and other neurotherapies for treatment-resistant depression. Closely comparable to Nushama in multi-modality brain-stimulation approach and outpatient clinic delivery.

TypeEmerging player
Description

Innerwell is a virtual psychiatry and ketamine-assisted therapy platform combining at-home ketamine treatment with integrative psychotherapy. Emerging competitor overlapping with Nushama on integration support and treatment-resistant mood disorders but delivered remotely.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nushama

Ketamine Therapy Clinicsnushama.com

Nushama operates a three-clinic psychedelic wellness network delivering medically supervised IV ketamine, FDA-approved Spravato, accelerated TMS, and NAD+ therapy for treatment-resistant depression, PTSD, anxiety, and trauma in the New York metro area and South Florida.

What Nushama does

Nushama is a privately held, for-profit operator of medically supervised psychedelic wellness clinics founded in 2021 and headquartered at 515 Madison Avenue, New York, with 11–50 employees (per LinkedIn). It runs a three-location network — Midtown Manhattan, Rockland County NY, and Aventura FL — delivering IV ketamine infusions, FDA-approved Spravato (esketamine), accelerated One-Day TMS, NAD+ IV therapy, and Niagen (NR) therapy to patients with treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, postpartum depression, migraines, suicidal ideation, palliative care needs, and alcohol use disorder. Treatment protocols follow a structured arc — psychiatric and medical intake, preparation sessions, six IV ketamine sessions over three to six weeks (or Spravato induction twice weekly for four weeks with weekly maintenance), continuous vital-sign monitoring, and integration coaching — augmented by a published 2025 real-world PTSD outcomes study (75.21% clinically meaningful improvement, 61.54% full remission) and a KARE partnership with Awakn Life Sciences for alcohol use disorder.

The revenue model is hybrid professional-services and subscription/recurring: IV ketamine and TMS are predominantly out-of-pocket session fees (typically six-session protocols); Spravato is in-network with Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare; NAD+ and Niagen are per-session or bundled add-ons; financing is available via CareCredit and HSA/FSA. Pricing accessibility is extended through the Hero's Journey scholarship program (a 25% discount for first responders and veterans) and monthly financial-based scholarships. Go-to-market combines direct-to-consumer intake, healthcare provider referrals via a dedicated for-providers portal, and community-led growth (bi-weekly integration circles, PR coverage in the NYT, WSJ, Elle, Good Morning America, New York Magazine, and Forbes). Operations are supported by HIPAA-compliant privacy protocols, FDA REMS certification for Spravato, and DEA-licensed dosing oversight led by Chief Medical Officer Dr. Steven Radowitz, alongside co-founders Jay Godfrey and Richard Meloff.

Nushama firmographics

Firmographics
Name
Nushama
Legal name
Nushama
Website
https://nushama.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Nushama operates a three-clinic psychedelic wellness network delivering medically supervised IV ketamine, FDA-approved Spravato, accelerated TMS, and NAD+ therapy for treatment-resistant depression, PTSD, anxiety, and trauma in the New York metro area and South Florida.
Ownership category
akta.pro rank

Nushama industry classification

Industry
Product category
Ketamine Therapy Clinics
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYEDALAFAB
Mental Health Counseling & Psychotherapy Services
Education/Student Services & Campus Operations/Student Health, Counseling & Wellness Services
SECONDARYBPAGAEAO
Substance Use Recovery & Harm Reduction Support Services
Business & Public Services/Nonprofit, NGO & Social Services/Social Services & Community Support (Food, Housing, Family)

Keywords

  • Ketamine infusion therapy
  • Psychedelic wellness services
  • Treatment-resistant depression
  • Spravato esketamine treatment
  • Accelerated TMS therapy

Where Nushama is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Nushama business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

  1. IV Ketamine Infusions: Intravenous ketamine therapy administered in a clinic setting. Typically an out-of-pocket expense, though superbills can be provided for potential out-of-network insurance reimbursement. Six-session protocols generate recurring service revenue per patient.
  2. Spravato (Esketamine) Treatment: FDA-approved esketamine nasal spray for treatment-resistant depression and MDD with acute suicidal ideation. Covered by in-network insurance plans including Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance.
  3. One-Day TMS: Accelerated transcranial magnetic stimulation (TMS) services compressing typical six-week treatment into accelerated protocols for time-constrained patients. Revenue generated per session.
  4. NAD+ and Niagen Therapy: Cellular support therapies offered as complementary treatments to ketamine, potentially billed per session or as part of bundled treatment protocols.
  5. CareCredit Financing: Third-party patient financing through CareCredit for out-of-pocket treatments, enabling payment plans for patients who cannot afford full upfront costs.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyHero's Journey Program — 25% discount for first responders and veterans
SubscriptionMonthlyIntegration Circles — ongoing support included
One time/ perpetual licensePay-as-you-goCancellation Policy — Journey appointments

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Nushama product offering

Product offering

Core offering

Nushama operates a network of medically supervised psychedelic wellness clinics that administer intravenous (IV) ketamine infusions and Spravato (esketamine) nasal spray as primary treatments, supported by accelerated one-day transcranial magnetic stimulation (TMS), NAD+ IV therapy, and NIAGEN (NR) supplementation. Treatments target treatment-resistant depression, PTSD, anxiety, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, palliative care, and alcohol use disorder (via the KARE protocol under partnership with Awakn Life Sciences). Services are delivered across three physical clinic locations in Manhattan, Rockland County (NY), and Aventura (FL), with psychiatric intake, continuous medical monitoring, preparation sessions, six-session IV ketamine protocols over three to six weeks, and bi-weekly integration circles forming the standard treatment arc.

Product overview

Nushama is a network of medically-supervised psychedelic wellness clinics offering ketamine-assisted therapy for mental health conditions. The core offering consists of IV Ketamine Infusions and Spravato (FDA-approved esketamine nasal spray) for conditions including treatment-resistant depression, anxiety, PTSD, and trauma. Adjacent services include One-Day TMS (accelerated transcranial magnetic stimulation), NAD+ Therapy, and NIAGEN (NR) Therapy for cellular support. Treatment protocols include preparation sessions, six IV ketamine sessions over three to six weeks, medical monitoring, and integration support. Financial access programs include the Hero's Journey 25% discount for first responders and veterans, and monthly financial-based scholarships. The company operates three locations in New York City, Rockland County, and Aventura, Florida.

Differentiator

Problem solved

Functional benefit

Brands

  • Hero's Journey Program: Scholarship program offering 25% discount for first responders and veterans on all ketamine therapy services

Products and services

  • Ketamine Infusions Intravenous ketamine infusions administered in a medically supervised clinical setting for treatment-resistant depression, anxiety, PTSD, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, and other mood disorders; delivered as a six-session protocol over three to six weeks with preparation, continuous vital monitoring, and integration support. Typically paid out-of-pocket with superbills available for potential out-of-network insurance reimbursement.
  • Spravato (Esketamine) Treatment FDA-approved esketamine nasal spray for treatment-resistant depression and major depressive disorder with acute suicidal ideation, administered under FDA REMS supervision with two-hour post-administration observation. Induction phase requires twice-weekly sessions for four weeks, transitioning to weekly maintenance, and is covered in-network by Oxford, UnitedHealthcare, Cigna, Aetna, and Medicare.
  • One-Day TMS (Accelerated Transcranial Magnetic Stimulation) Accelerated transcranial magnetic stimulation protocol that compresses the typical multi-week TMS course into a single-day treatment for time-constrained patients such as executives and busy professionals, delivered as a complement or alternative to ketamine for rapid depression relief.
  • NAD+ IV Therapy Intravenous nicotinamide adenine dinucleotide (NAD+) infusions used to support cellular energy, neural recovery, and physical rehabilitation, offered as a complement to ketamine treatment or as a standalone cellular-recovery and longevity service.
  • NIAGEN (NR) Therapy Nicotinamide Riboside (Niagen/NR) supplementation therapy delivered to support cellular repair, mitochondrial function, and to complement the neuroplastic effects of ketamine treatment.
  • Hero's Journey Program Financial-assistance access program providing a 25% discount on all Nushama services for active-duty military, veterans, police officers, fire department members, EMT workers, nurses, and teachers, supporting evidence-led psychedelic therapy access for these populations.

Quantifiable outcome

  • 70-90% response rate for ketamine infusion vs. 30-60% for standard antidepressants
  • +4 more outcomes

Companies that use Nushama

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Nushama technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Nushama partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Awakn Life SciencescoreStrategic or Co-development PartnerNushama partnered with Awakn Life Sciences to offer the KARE (Ketamine-Assisted Rehabilitation and Enhancement) protocol for treating alcohol use disorder. The protocol demonstrated 86% efficacy for abstinence after six months in clinical trials — an unprecedented clinical study result. This partnership extends Nushama's evidence-based treatment portfolio with a rigorously studied psychedelic therapy protocol for addiction.
  • Rater8minorOthersNushama uses Rater8 for member reviews and testimonials, displaying review links and ratings from verified patients on team member profile pages (Dr. Steven Radowitz, Dr. Robert Glatter, Dr. Mark Braunstein). Review links are prominently displayed on the website to build credibility and social proof.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Nushama competitors and assessment

Company assessment

Broad incumbents

  • Spravato (Janssen / Johnson & Johnson): Janssen's Spravato (esketamine) is the FDA-approved nasal spray version of ketamine that Nushama also administers under REMS. As the pharmaceutical incumbent, Spravato defines the regulatory and reimbursement landscape within which Nushama operates its IV ketamine and esketamine services.
  • Compass Pathways: Compass Pathways is a clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Broader psychedelic therapy incumbent that competes for the same patient population and share-of-mind in psychedelic-assisted mental health treatment.

Regional players

  • Restore Hyper Wellness: Restore Hyper Wellness operates a national franchise of wellness centers offering IV therapy, NAD+, cryotherapy, and other recovery modalities. Comparable in NAD+ and longevity-adjacent service offerings and franchise-style clinic delivery, though Restore focuses on wellness more than psychiatric care.

Direct peers

  • Field Trip Health: Field Trip Health was a publicly listed psychedelic therapy clinic network offering ketamine-assisted psychotherapy in premium locations across North America. Closest historical direct peer to Nushama in clinic model, target patient, and therapy modality.
  • Mindbloom: Mindbloom is a leading at-home ketamine therapy provider offering guided psychedelic treatment via telehealth and remote clinician supervision. Direct competitor for ketamine-treated mood disorders, competing for the same patient demographic with a different delivery model.
  • Better U (formerly known as Keta Medical Center): Better U operates ketamine therapy clinics offering supervised IV ketamine treatments for mood disorders, anxiety, and PTSD in a clinical setting. Direct peer in outpatient ketamine clinic model targeting treatment-resistant populations.
  • Ketamine Clinics of Los Angeles (KCLA): KCLA is one of the oldest and largest ketamine-only specialty outpatient clinics in the U.S., offering IV ketamine protocols for depression, PTSD, and chronic pain. Direct peer in clinic-based ketamine therapy for treatment-resistant mental health conditions.
  • Actify Neurotherapies: Actify operates a national network of clinics offering ketamine infusion therapy combined with TMS and other neurotherapies for treatment-resistant depression. Closely comparable to Nushama in multi-modality brain-stimulation approach and outpatient clinic delivery.

Others

  • Awakn Life Sciences: Awakn Life Sciences is a clinical-stage psychedelics company whose KARE protocol for alcohol use disorder Nushama licenses and delivers clinically. Direct partnership counterparty and adjacent specialty psychedelic therapeutics developer.

Emerging players

  • Innerwell: Innerwell is a virtual psychiatry and ketamine-assisted therapy platform combining at-home ketamine treatment with integrative psychotherapy. Emerging competitor overlapping with Nushama on integration support and treatment-resistant mood disorders but delivered remotely.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Nushama social profiles

Digital presence

Nushama compliance and trust

Trust signal

Compliance2 records

Nushama financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nushama leadership team

Management profile

Number of profiles

Profiles5 records

Nushama funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nushama M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nushama

What does Nushama do?

Nushama operates a network of medically supervised psychedelic wellness clinics that administer intravenous (IV) ketamine infusions and Spravato (esketamine) nasal spray as primary treatments, supported by accelerated one-day transcranial magnetic stimulation (TMS), NAD+ IV therapy, and NIAGEN (NR) supplementation. Treatments target treatment-resistant depression, PTSD, anxiety, OCD, eating disorders, suicidal ideation, postpartum depression, migraines, burnout, palliative care, and alcohol use disorder (via the KARE protocol under partnership with Awakn Life Sciences). Services are delivered across three physical clinic locations in Manhattan, Rockland County (NY), and Aventura (FL), with psychiatric intake, continuous medical monitoring, preparation sessions, six-session IV ketamine protocols over three to six weeks, and bi-weekly integration circles forming the standard treatment arc.

Is Nushama a public or private company?

Nushama is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nushama founded?

Nushama was founded in 2021. It employs 11 to 50 people.

Where is Nushama based?

Nushama is headquartered in New York, United States, in the North America region.

How does Nushama make money?

Five revenue lines are on record. IV Ketamine Infusions are the primary driver. The others are spravato (Esketamine) Treatment, one-Day TMS, NAD+ and Niagen Therapy and careCredit Financing.

Who are Nushama's main competitors?

Broad incumbents on record are Spravato (Janssen / Johnson & Johnson) and Compass Pathways. Restore Hyper Wellness is listed as a regional player. Direct peers are Field Trip Health, Mindbloom, Better U (formerly known as Keta Medical Center), Ketamine Clinics of Los Angeles (KCLA) and Actify Neurotherapies. Awakn Life Sciences is listed as an others. Innerwell is listed as an emerging player.

Does Nushama have an API?

No public API is recorded for Nushama.

What industry is Nushama in?

Nushama's product category is Ketamine Therapy Clinics. Its primary akta.pro industry code is EDALAFAB, Mental Health Counseling & Psychotherapy Services, with a secondary code of BPAGAEAO, Substance Use Recovery & Harm Reduction Support Services. Its NAICS code is 621420 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NBC 6 South FloridaKetamine therapy arrives in Aventura: How alternative medicine is the futureNushama has opened a ketamine therapy clinic in Aventura, capitalizing on federal government initiatives to explore alternative mental health treatments. The clinic reports having administered treatment to over 3,000 patients, while medical experts highlight the procedure's potential benefits alongside risks such as addiction and adverse physical effects.BenzingaPsychedelic Treatments Vary Greatly By Cost And Setting, What About Efficacy? - Alphabet (NASDAQ:GOOGL)The psychedelic therapy market is expanding with treatment settings ranging from traditional indigenous ceremonies costing under $100 to luxury resort retreats priced between $4,300 and $8,000, and urban clinics like Nushama charging $4,500 for six-session treatment protocols. The article highlights significant variation in pricing, setting types, and approaches across providers including MycoMeditations in Jamaica, Nushama in New York, and Beond for ibogaine treatment, while noting that efficacy remains largely unmeasured and subjective. Industry observers recommend thorough research and caution that access to authentic experiences often remains limited to upper-middle-class consumers despite calls for affordability and indigenous inclusion.The New York TimesThis Wellness Center Uses Ketamine for Mental HealthNushama, a New York City wellness clinic, offers ketamine treatments for mental health, operating under limited FDA oversight. The clinic's series of sessions now costs $4,500 and includes a seventh session. Ketamine is not FDA-approved for mental health, though it is prescribed as a sedative.